GLI1 and neoplasm: The 1-year, 2-year, and 3-year DFS rates for the Gli-1 nuclear expression group vs the Gli-1-null or cytoplasmic expression or no residual tumour group were 16.7 vs 68.9%, 0 vs 54.9%, and 0 vs 47.8%, respectively; the corresponding 1-year, 2-year, and 3-year OS rates were 33.3 vs 82.8%, 16.7 vs 54.9%, and 0 vs 46.1%.